Remestemcel-L
- Generic Name
- Remestemcel-L
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- H57D26Z9YK
- Background
Remestemcel-L is a third-party, off-the-shelf suspension of ex-vivo cultured adult human mesenchymal stem cells intended for intravenous infusion. The mesenchymal stem cells are derived from the bone marrow of unrelated and human leukocyte antigen (HLA)–unmatched healthy adult donors and have the ability to differentiate into different tissue cells. It was a...
- Indication
Indicated for in the management of acute Graft versus Host Disease (aGvHD) in pediatric patients. Acute GvHD should be refractory to treatment with systemic corticosteroid therapy and/or other immunosuppressive agents. Remestemcel-L may be used for Grades C and D of the disease in any organ. Remestemcel-L may also be used in the management of Grade B aGvHD i...
- Associated Conditions
- Acute, refractory Graft Versus Host Disease
- Associated Therapies
- -
Study of Mesenchymal Stem Cells for the Treatment of Medically Refractory Crohn's Colitis
- First Posted Date
- 2020-09-14
- Last Posted Date
- 2022-04-05
- Lead Sponsor
- The Cleveland Clinic
- Target Recruit Count
- 24
- Registration Number
- NCT04548583
- Locations
- 🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States
Study of Mesenchymal Stem Cells for the Treatment of Medically Refractory Ulcerative Colitis (UC)
- First Posted Date
- 2020-09-10
- Last Posted Date
- 2022-04-05
- Lead Sponsor
- The Cleveland Clinic
- Target Recruit Count
- 24
- Registration Number
- NCT04543994
- Locations
- 🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States
Intermediate-size Expanded Access Program (EAP), Mesenchymal Stromal Cells (MSC) for Acute Respiratory Distress Syndrome (ARDS) Due to COVID-19 Infection
- First Posted Date
- 2020-04-29
- Last Posted Date
- 2021-02-18
- Lead Sponsor
- Mesoblast International Sàrl
- Registration Number
- NCT04366830
- Locations
- 🇺🇸
Mount Sinai Hospital, New York, New York, United States
A Prospective Study of Remestemcel-L, Ex-vivo Cultured Adult Human Mesenchymal Stromal Cells, for the Treatment of Pediatric Participants Who Have Failed to Respond to Steroid Treatment for Acute Graft-Versus-Host Disease (aGVHD)
- First Posted Date
- 2015-01-12
- Last Posted Date
- 2022-03-17
- Lead Sponsor
- Mesoblast, Inc.
- Target Recruit Count
- 55
- Registration Number
- NCT02336230
- Locations
- 🇺🇸
Virginia Commonwealth University, Richmond, Virginia, United States
🇺🇸University of Mississippi Medical Center, Jackson, Mississippi, United States
🇺🇸Fred Hutchinson Cancer Research, Seattle, Washington, United States
Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease
- First Posted Date
- 2010-11-03
- Last Posted Date
- 2021-12-08
- Lead Sponsor
- Mesoblast, Inc.
- Target Recruit Count
- 73
- Registration Number
- NCT01233960
- Locations
- 🇦🇺
Royal Melbourne Hospital, Melbourne, Victoria, Australia
🇺🇸Shafran Gastroenterology Center, Winter Park, Florida, United States
🇺🇸Vanderbilt University Medical Center, Nashville, Tennessee, United States
Prochymal™ Adult Human Mesenchymal Stem Cells for Treatment of Moderate-to-severe Crohn's Disease
- Conditions
- Interventions
- First Posted Date
- 2006-02-20
- Last Posted Date
- 2020-04-02
- Lead Sponsor
- Mesoblast, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT00294112
- Locations
- 🇺🇸
Osiris Clinical Site, Richmond, Virginia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.